Role of carnosine in peripheral arterial disease
Active Project Grant Awarded Last action
- Award ID
- R01HL163419
- Recipient
-
University Of Louisville UEI E1KJM4T54MK6
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,938,898
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 47% complete
- Place of performance
- Louisville, KY 40202, USA
Award details come from USAspending.gov.
Description
- Abstract
- Peripheral arterial disease is a serious manifestation of atherosclerosis in the lower extremities. Current interventions approved by FDA are either ineffective or have a modest effect. Surgical revascularization is the only viable option for pad subjects; however, the stents can fail. Patients with pad have marked defects in skeletal muscle metabolism, where the aerobic and anaerobic metabolism are uncoupled, increased acidification of the skeletal muscle and decreased ATP synthesis. In glycolytically active tissue, such as skeletal muscle, there are present histidyl dipeptides, such as carnosine which buffers intracellular PH, under ischemic conditions and facilitate the utilization of glucose during exercise and ischemia. Recent evidence from our laboratory shows that in addition to buffering, carnosine chelates first transition metals and improves angiogenesis, forms conjugates with reactive aldehydes derived from lipid peroxidation and regress atherosclerosis. Hence enhancing carnosine via supplementation, which easily permeates through the ischemic muscle, is easily could be a feasible therapeutic that can target the underlying pathophysiological associated with pad and increase limb function. To achieve this goal, we will treat the pad subjects with carnosine and examine whether the carnosine supplementation improves the lower extremity function. Second, we will perform extensive mechanistic studies to elucidate the mechanism by which carnosine improves the muscle function and finally we will follow these subjects and determine if carnosine has durable effects. Collectively, our pilot clinical trial will help US test the efficacy of carnosine as a low-cost therapeutic intervention for pad patients and the data generated will serve as a strong rationale to design large definitive phase III clinical trial for carnosine.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $632,838 | |
| Amendment | $645,860 | |
| Original award | $660,200 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Cincinnati Univ Of | $25,536 | |
| Cincinnati Univ Of | $33,374 | |
| Cincinnati Univ Of | $44,496 |
Quick answers
Who received award R01HL163419?
R01HL163419 was awarded to University Of Louisville by National Heart Lung and Blood Institute (National Institutes of Health) on August 15, 2024.
How much is award R01HL163419 worth?
$1,938,898 has been obligated on R01HL163419.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award